The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

Details for the poster presentation: Title: TACTI-004: a double-blinded, randomized phase 3 trial in patients with advanced/metasttic non-small cell cancer receiving eftilagimod alfa (MHC class II ...

Vitamins have been a part of our lives for generations, haven't they? From the bright orange chewable vitamin C tablets of childhood to the little capsules tucked into kitchen cabinets, they've always ...

Now, as a scientist at the University of Pennsylvania, Charly is working to rewrite the future of cancer treatment.

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, cutting preclinical programs and evaluating strategic options. | Despite a ...

Older patients and those with genetic risk factors were at particularly high risk of relapse and had poorer overall survival.

Antibodies, which recognize viruses and proteins that the body has encountered before, have long gotten most of the credit ...

New imaging reveals a built-in safeguard that allows B cell populations to rapidly expand in germinal centers without introducing deleterious mutations.

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...